ClinicalTrials.Veeva

Menu
Instituto Medico Platense | Clinical Research Department logo

Instituto Medico Platense | Clinical Research Department

Research site

Site insights

Top conditions

Top treatments

Oseltamivir
EDP-938
Pimodivir
Contezolid
Ustekinumab
Taxane
Lumicitabine
Ribavirin
Baloxavir Marboxil
Vancomycin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

5 of 28 total trials

A Study of EDP-938 in Non-hospitalized Adults with RSV Who Are At High Risk for Complications. (RSVHR)

This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult sub...

Enrolling
RSV Infection
Drug: Placebo
Drug: EDP-938

The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juven...

Enrolling
Arthritis, Juvenile
Drug: Guselkumab
Drug: Ustekinumab

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting
Respiratory Syncytial Virus
Drug: Placebo
Drug: mRNA-1345

This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linez...

Enrolling
Diabetic Foot Infection
Drug: contezolid acefosamil (IV)/contezolid (PO)
Drug: Linezolid (IV and PO)

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Enrolling
Lower Respiratory Tract Illness
Biological: RSVpreF
Biological: Placebo

Trial sponsors

Janssen (J&J Innovative Medicine) logo
University of Minnesota (UMN) logo
Enanta Pharmaceuticals logo
Moderna logo
Roche logo
Bristol-Myers Squibb (BMS) logo
Corvus Pharmaceuticals logo
Dompé logo
Janssen (J&J Innovative Medicine) logo
MicuRx logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems